| # | Drug | Count |
|---|---|---|
| 0 | DURVALUMAB | 11 |
| 1 | THIOTEPA | 11 |
| 2 | FLUOROURACIL | 9 |
| 3 | FLUOROURACIL CREAM, 0.5% | 9 |
| 4 | OXALIPLATIN | 9 |
| 5 | BEVACIZUMAB | 6 |
| 6 | CAPECITABINE | 6 |
| 7 | PEMETREXED DISODIUM | 6 |
| 8 | CARBOPLATIN | 5 |
| 9 | CETUXIMAB | 5 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | THIOTEPA | 11 | 0.0011 |
| 1 | FLUCYTOSINE | 1 | 0.0007 |
| 2 | DURVALUMAB | 11 | 0.0005 |
| 3 | IMIPENEM AND CILASTATIN SODIUM | 1 | 0.0005 |
| 4 | DACTINOMYCIN | 1 | 0.0005 |
| 5 | INOTUZUMAB OZOGAMICIN | 1 | 0.0003 |
| 6 | TEMOZOLOMIDE | 5 | 0.0002 |
| 7 | BLEOMYCIN SULFATE | 2 | 0.0002 |
| 8 | OXCARBAZEPINE | 3 | 0.0002 |
| 9 | HYDROXYUREA | 4 | 0.0002 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Nucleoside Analog Antifungal [EPC] | 1 | 0.0007 |
| 1 | Programmed Death Ligand-1 Blocker [EPC] | 11 | 0.0005 |
| 2 | Actinomycin [EPC] | 1 | 0.0005 |
| 3 | CD22-directed Immunoconjugate [EPC] | 1 | 0.0003 |
| 4 | Epidermal Growth Factor Receptor Antagonist [EPC] | 5 | 0.0001 |
| 5 | Alkylating Drug [EPC] | 19 | 0.0001 |
| 6 | Lipid-based Polyene Antifungal [EPC] | 1 | 0.0001 |
| 7 | Platinum-based Drug [EPC] | 17 | 0.0001 |
| 8 | Human Immunoglobulin G [EPC] | 1 | 0.0000 |
| 9 | Nucleoside Metabolic Inhibitor [EPC] | 12 | 0.0000 |